Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Clinical Therapeutics

• Publication date

  2013-05-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1016/j.clinthera.2013.03.016PMID 23587608
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey.

  2018cited by this paper
• Opioids for neuropathic pain.

  2013cited by this paper
• PSY1 Tolerability of Oral Long-Acting Opioids in the Treatment of Chronic Pain: a Systematic Literature Review and Meta-Analysis

  2011cited by this paper
• Mu‐opioid and noradrenergic &agr;2‐adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve‐injured rats

  2011cited by this paper
• Interval Signet-Ring Cell Adenocarcinoma of the Colon: Missed or De Novo?

  2011cited by this paper
• Prospects and challenges in opioid analgesia for pain management

  2011cited by this paper
• Effectiveness of long-term opioid therapy for chronic non-cancer pain.

  2011cited by this paper
• Long‐term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain

  2010cited by this paper
• Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians.

  2010cited by this paper
• Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

  2010cited by this paper
• Burden of opioid-associated gastrointestinal side effects from clinical and economic perspectives: a systematic literature review.

  2010cited by this paper
• Practice Guidelines for Chronic Pain Management: An Updated Report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine*

  2010cited by this paper
• Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?

  2010cited by this paper
• Costs of Gastrointestinal Events after Outpatient Opioid Treatment for Non-Cancer Pain

  2010cited by this paper
• Long-term opioid management for chronic noncancer pain.

  2010cited by this paper
• Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee

  2010cited by this paper
• Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation.

  2010cited by this paper
• The direct and indirect costs of opioid-induced constipation.

  2010cited by this paper
• Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

  2009cited by this paper
• Peripherally Acting Mu-Opioid Receptor Antagonists and Postoperative Ileus: Mechanisms of Action and Clinical Applicability

  2009cited by this paper
• PSY13 FREQUENCY AND BOTHERSOMENESS OF SIDE EFFECTS IN PAIN PATIENTS TAKING OXYCODONE IMMEDIATE RELEASE: IMPACT ON PRESCRIPTION AND OVER-THE-COUNTER MEDICATION USE

  2009cited by this paper
• A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs.

  2009cited by this paper
• Managing chronic pain: what's the best approach?

  2008cited by this paper
• Meeting the Challenges of Opioid-Induced Constipation in Chronic Pain Management – A Novel Approach

  2008cited by this paper
• Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society

  2007cited by this paper
• Opioid analgesia: perspectives on right use and utility.

  2007cited by this paper
• Opioid-Related Adverse Drug Events in Surgical Hospitalizations: Impact on Costs and Length of Stay

  2007cited by this paper
• (–)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties

  2007cited by this paper
• Chronic low back pain: epidemiology, economic burden and patient-reported outcomes in the USA

  2006cited by this paper
• Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial.

  2006cited by this paper
• Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany

  2006cited by this paper
• Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

  2006cited by this paper
• Management of common opioid-induced adverse effects.

  2006cited by this paper
• Opioids for neuropathic pain.

  2006cited by this paper
• Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids

  2005cited by this paper
• National Center for Health Statistics (NCHS)

  2005cited by this paper
• Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study

  2005cited by this paper
• Opioids in chronic non‐cancer pain: systematic review of efficacy and safety

  2004cited by this paper
• Use of opioid analgesics for the treatment of chronic noncancer pain--a consensus statement and guidelines from the Canadian Pain Society, 2002.

  2003cited by this paper
• Lost productive time and cost due to common pain conditions in the US workforce.

  2003cited by this paper
• Health, United States 2003: With Chartbook on Trends in the Health of Americans

  2003cited by this paper
• Cost of opioid-related adverse drug events in surgical patients.

  2003cited by this paper
• Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis.

  2002cited by this paper
• Opioid-induced emesis among hospitalized nonsurgical patients: effect on pain and quality of life.

  1999cited by this paper
• The labor productivity effects of chronic backache in the United States.

  1998cited by this paper
• Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy.

  1994cited by this paper
• Statistical abstract of the United States

  1978cited by this paper
• Prospects and challenges.

  1967cited by this paper

• Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study

  2022cites this paper
• Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients

  2021cites this paper
• Risk indicators in tapentadol use: opportunities to improve outcomes with a personal pharmaceutical care approach in community pharmacies

  2021cites this paper
• Opioid Treatments for Chronic Pain

  2020cites this paper
• Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012–2016

  2019cites this paper
• Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study

  2019cites this paper
• Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain

  2017cites this paper
• A Methodological Review of US Budget-Impact Models for New Drugs

  2016influential citation
• Budget impact analysis of medicines: updated systematic review and implications

  2016cites this paper
• Endogenous opiates and behavior: 2014.

  2016cites this paper
• Comparison of Real-world Outcomes Between Patients Treated with Tapentadol ER or Oxycodone CR

  2015cites this paper
• Economic evaluation in chronic pain: a systematic review and de novo flexible economic model

  2015cites this paper
• Chronic pain: the burden of disease and treatment innovations.

  2015cites this paper
• Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans

  2014cites this paper
• Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain

  2014cites this paper
• Pain therapeutics in older adults.

  2013cites this paper
• Current Considerations for the Treatment of Severe Chronic Pain: The Potential for Tapentadol

  2012cites this paper